S. S. Arnon, R. Schechter, T. V. Inglesby, D. A. Henderson, J. G. Bartlett et al., Botulinum toxin as a biological weapon: Medical and public health management, JAMA, vol.285, pp.1059-1070, 2001.

D. Sesardic, R. G. Jones, T. Leung, T. Alsop, and R. Tierney, Detection of antibodies against botulinum toxins, Mov. Disord, vol.19, pp.85-91, 2004.

C. L. Hatheway, Clostridium botulinum and other clostridia that produce botulinum neurotoxin

, Clostridium botulinum

A. H. Hauschild and K. L. Doods, , vol.13, pp.3-20, 1993.

M. Lindström and H. Korkeala, Laboratory diagnostics of botulism, Clin. Microbiol. Rev, vol.19, pp.298-314, 2006.

M. W. Peck, Biology and genomic analysis of Clostridium botulinum, Adv. Microb. Physiol, vol.55, pp.183-320, 2009.

K. K. Hill and T. J. Smith, Genetic diversity within Clostridium botulinum serotypes, botulinum neurotoxin gene clusters and toxin subtypes, Botulinum Neurotoxins

A. Rummel and T. Binz, , vol.364, pp.1-20, 2013.

J. R. Barash and S. S. Arnon, A novel strain of Clostridium botulinum that produces type B and type H botulinum toxins, J. Infect. Dis, vol.209, pp.183-191, 2014.

N. Dover, J. R. Barash, K. K. Hill, G. Xie, and S. S. Arnon, Molecular characterization of a novel botulinum neurotoxin type H gene, J. Infect. Dis, vol.209, pp.192-202, 2014.

S. E. Maslanka, C. Luquez, J. K. Dykes, W. H. Tepp, C. L. Pier et al., A novel botulinum neurotoxin, previously reported as serotype H, has a hybrid-like structure with regions of similarity to the structures of serotypes A and F and is neutralized with serotype A antitoxin, J. Infect. Dis, vol.213, pp.379-385, 2015.

Y. Chen, H. Korkeala, J. Aarnikunnas, and M. Lindström, Sequencing the botulinum neurotoxin gene and related genes in Clostridium botulinum type E strains reveals orfx3 and a novel type E neurotoxin subtype, J. Bacteriol, vol.189, pp.8643-8650, 2007.

A. Couesnon, S. Raffestin, and M. R. Popoff, Expression of botulinum neurotoxins A and E, and associated non-toxin genes, during the transition phase and stability at high temperature: Analysis by quantitative reverse transcription-PCR. Microbiology, vol.152, pp.759-770, 2006.

J. W. Froude, B. G. Stiles, T. Pelat, and P. Thullier, Antibodies for biodefense, vol.3, pp.517-527, 2011.

W. Rosenau, Aum shinrikyo's biological weapons program: Why did it fail? Stud, Confl. Terror, vol.24, pp.289-301, 2001.

G. Sakaguchi, Clostridium botulinum toxins, Pharmacol. Ther, vol.19, pp.165-194, 1982.

M. R. Popoff and P. Bouvet, Genetic characteristics of toxigenic clostridia and toxin gene evolution, Toxicon, vol.75, pp.63-89, 2013.
URL : https://hal.archives-ouvertes.fr/pasteur-01793259

N. Yokosawa, K. Tsuzuki, B. Syuto, and K. Oguma, Activation of Clostridium botulinum type E toxin purified by two different procedures, J. Gen. Microbiol, vol.132, 1981.

R. Pellizzari, O. Rossetto, G. Schiavo, and C. Montecucco, Tetanus and botulinum neurotoxins: Mechanism of action and therapeutic uses, Philos Trans. R. Soc. Lond. B Biol. Sci, vol.354, pp.259-268, 1999.

C. Montecucco, How do tetanus and botulinum toxins bind to neuronal membranes?, Trends Biochem. Sci, vol.11, pp.314-317, 1986.

Y. Humeau, F. Doussau, N. J. Grant, and B. Poulain, How botulinum and tetanus neurotoxins block neurotransmitter release, Biochimie, vol.82, pp.427-446, 2000.

L. L. Simpson, Identification of the major steps in botulinum toxin action, Annu. Rev. Pharmacol. Toxicol, vol.44, pp.167-193, 2004.

G. Schiavo, M. Matteoli, and C. Montecucco, Neurotoxins affecting neuroexocytosis, Physiol. Rev, vol.80, pp.717-766, 2000.

M. Elias, F. Al-saleem, D. M. Ancharski, A. Singh, Z. Nasser et al., Evidence that botulinum toxin receptors on epithelial cells and neuronal cells are not identical: Implications for development of a non-neurotropic vaccine, J. Pharmacol. Exp. Ther, vol.336, pp.605-612, 2011.

M. Pirazzini, D. A. Tehran, G. Zanetti, F. Lista, T. Binz et al., The thioredoxin reductase-Thioredoxin redox system cleaves the interchain disulphide bond of botulinum neurotoxins on the cytosolic surface of synaptic vesicles, Toxicon, vol.107, pp.32-36, 2015.

R. Jones, M. Ochiai, Y. Liu, T. Ekong, and D. Sesardic, Development of improved SNAP25 endopeptidase immuno-assays for botulinum type A and E toxins, J. Immunol. Methods, vol.329, pp.92-101, 2008.

D. Leclair, J. M. Farber, B. Doidge, B. Blanchfield, S. Suppa et al., Distribution of Clostridium botulinum type E strains in Nunavik, Canada. Appl. Environ. Microbiol, vol.79, pp.646-654, 2013.

S. Hielm, E. Hyytiä, A. Andersin, and H. Korkeala, A high prevalence of Clostridium botulinum type E in Finnish freshwater and Baltic Sea sediment samples, J. Appl. Microbiol, vol.84, pp.133-137, 1998.

E. Hyytiä, S. Hielm, J. Björkroth, and H. Korkeala, Biodiversity of Clostridium botulinum type E strains isolated from fish and fishery products, Appl. Environ. Microbiol, vol.65, pp.2057-2064, 1999.

S. Hielm, J. Björkroth, E. Hyytiä, and H. Korkeala, Prevalence of Clostridium botulinum in Finnish trout farms: Pulsed-field gel electrophoresis typing reveals extensive genetic diversity among type E isolates, Appl. Environ. Microbiol, vol.64, pp.4161-4167, 1998.

L. A. King, T. Niskanen, M. Junnikkala, E. Moilanen, M. Lindström et al., Botulism and hot-smoked whitefish: A family cluster of type E botulism in France, Euro Surveill, vol.14, pp.429-433, 2009.

M. Lindström, M. Vuorela, K. Hinderink, H. Korkeala, E. Dahlsten et al., Botulism associated with vacuum-packed smoked whitefish in Finland, Euro Surveill, p.23, 2006.

C. Mazuet, J. Sautereau, C. Legeay, C. Bouchier, P. Bouvet et al., An atypical outbreak of food-borne botulism due to clostridium botulinum types B and E from ham, J. Clin. Microbiol, vol.53, pp.722-726, 2015.
URL : https://hal.archives-ouvertes.fr/pasteur-01768473

L. L. Simpson and B. R. Dasgupta, Botulinum neurotoxin type E: Studies on mechanism of action and on structure-activity relationships, J. Pharmacol. Exp. Ther, vol.224, pp.135-140, 1983.

S. S. Arnon, Human Tetanus and Human Botulism, In Clostridia: Molecular Biology and Pathogenesis

J. Rood, B. Mc-clane, and J. Songer, , pp.95-111, 1997.

M. Cherington, Clinical spectrum of botulism, Muscle Nerve, vol.21, pp.701-710, 1998.

F. A. Meunier, G. Schiavo, and J. Molgó, Botulinum neurotoxins: From paralysis to recovery of functional neuromuscular transmission, J. Physiol, vol.96, pp.105-113, 2002.
URL : https://hal.archives-ouvertes.fr/hal-00193833

S. S. Arnon, R. Schechter, S. E. Maslanka, N. P. Jewell, and C. L. Hatheway, Human botulism immune globulin for the treatment of infant botulism, N. Engl. J. Med, vol.354, pp.462-471, 2006.

, Investigational heptavalent botulinum antitoxin (HBAT) to replace licensed botulinum antitoxin AB and investigational botulinum antitoxin E, Centers for Disease Control and Prevention (CDC), p.299, 2010.

R. E. Black and R. A. Gunn, Hypersensitivity reactions associated with botulinal antitoxin, Am. J. Med, vol.69, pp.567-570, 1980.

R. G. Hibbs, J. T. Weber, A. Corwin, B. M. Allos, M. S. Abd-el-rehim et al., Experience with the use of an investigational F(ab')2 heptavalent botulism immune globulin of equine origin during an outbreak of type E botulism in Egypt, Clin. Infect. Dis, vol.23, pp.337-340, 1996.

T. Pelat and P. Thullier, Non-human primate immune libraries combined with germline humanization: An (almost) new and powerful approach for the isolation of therapeutic antibodies, vol.1, pp.377-381, 2009.

P. Tan, D. A. Mitchell, T. N. Buss, M. A. Holmes, C. Anasetti et al., Superhumanized" antibodies: Reduction of immunogenic potential by complementarity-determining region grafting with human germline sequences: Application to an anti-CD28, J. Immunol, vol.169, pp.1119-1125, 2002.

G. T. Williams, C. J. Jolly, J. Köhler, and M. S. Neuberger, The contribution of somatic hypermutation to the diversity of serum immunoglobulin: Dramatic increase with age, Immunity, vol.13, pp.409-417, 2000.

T. Pelat, H. Bedouelle, A. R. Rees, S. J. Crennell, M. Lefranc et al., Germline humanization of a non-human primate antibody that neutralizes the anthrax toxin, by in vitro and in silico engineering, J. Mol. Biol, vol.384, pp.1400-1407, 2008.
URL : https://hal.archives-ouvertes.fr/hal-00345933

R. Robert, V. A. Streltsov, J. Newman, L. A. Pearce, K. L. Wark et al., Germline humanization of a murine A? antibody and crystal structure of the humanized recombinant Fab fragment, Protein Sci, vol.19, pp.299-308, 2010.

S. Miethe, C. Rasetti-escargueil, A. Avril, Y. Liu, S. Chahboun et al., Development of human-like scFv-fc neutralizing botulinum neurotoxin E, PLoS ONE, vol.10, 2015.
URL : https://hal.archives-ouvertes.fr/pasteur-01325687

L. J. Rosenwasser, W. W. Busse, R. G. Lizambri, T. A. Olejnik, and M. C. Totoritis, Allergic asthma and an anti-CD23 mAb (IDEC-152): Results of a phase I, single-dose, dose-escalating clinical trial, J. Allergy Clin. Immunol, vol.112, pp.563-570, 2003.

S. Miethe, C. Mazuet, Y. Liu, R. Tierney, C. Rasetti-escargueil et al., Development of germline-humanized antibodies neutralizing botulinum neurotoxin A and B, PLoS ONE, 2016.
URL : https://hal.archives-ouvertes.fr/pasteur-01784826

J. C. Byrd, S. O'brien, I. W. Flinn, T. J. Kipps, M. Weiss et al., Phase 1 study of lumiliximab with detailed pharmacokinetic and pharmacodynamic measurements in patients with relapsed or refractory chronic lymphocytic leukemia, Clin. Cancer Res, vol.13, pp.4448-4455, 2007.

M. Hust, T. Meyer, B. Voedisch, T. Rülker, H. Thie et al., A human scFv antibody generation pipeline for proteome research, J. Biotechnol, vol.152, pp.159-170, 2011.

B. Thyagarajan, P. Gopalakrishnakone, M. Balali-mood, and R. Singh, Antidotes to botulinum neurotoxin, In Biological Toxins and Bioterrorism, pp.376-397, 2015.

L. A. Smith, Botulism and vaccines for its prevention, vol.27, pp.33-39, 2009.

J. M. Rusnak and L. A. Smith, Botulinum neurotoxin vaccines: Past history and recent developments, vol.5, pp.794-805, 2009.

K. A. Foster, Molecular Aspects of Botulinum Neurotoxin, 2014.

R. P. Fagan, K. P. Neil, R. Sasich, C. Luquez, H. Asaad et al., Initial recovery and rebound of type F intestinal colonization botulism after administration of investigational heptavalent botulinum antitoxin, Clin. Infect. Dis, vol.53, pp.125-128, 2011.

. Imgt/v-quest-online and . Tool, , 2016.

V. Jäger, K. Büssow, A. Wagner, S. Weber, M. Hust et al., High level transient production of recombinant antibodies and antibody fusion proteins in HEK293 cells, BMC Biotechnol, vol.13, pp.52-71, 2013.

S. Sibéril, C. Dutertre, C. Boix, E. Bonnin, R. Ménez et al., Molecular aspects of human Fc?R interactions with IgG: Functional and therapeutic consequences, Immunol. Lett, vol.106, pp.111-118, 2006.

K. Tsuji, K. A. Steindler, and S. J. Harrison, Limulus amoebocyte lysate assay for detection and quantitation of endotoxin in a small-volume parenteral product, Appl. Environ. Microbiol, vol.40, pp.533-538, 1980.

A. Guttman, On the separation mechanism of capillary sodium dodecyl sulfate-gel electrophoresis of proteins, Electrophoresis, vol.16, pp.611-616, 1995.

Z. Szabo, A. Guttman, J. Bones, and B. L. Karger, Rapid high-resolution characterization of functionally important monoclonal antibody N-glycans by capillary electrophoresis, Anal. Chem, vol.83, pp.5329-5336, 2011.

R. G. Jones, T. A. Alsop, R. Hull, R. Tierney, J. Holley et al., Botulinum type A toxin neutralisation by specific IgG and its fragments: A comparison of mouse systemic toxicity and local flaccid paralysis assays, Toxicon, vol.48, pp.246-254, 2006.